Pfizer and Moderna Expand Clinical Trials of COVID-19 Vaccine in Children Ages 5-11

BREAKING NEWS: Pfizer and Moderna Expand Clinical Trials of COVID-19 Vaccine in Children Ages 5-11 at FDA Urge

  • Pfizer-BioNTech and Moderna are being asked by the FDA to expand the number of children aged 5-11 in their COVID-19 vaccine clinical trials
  • Currently, the companies have 3,000 children each, but the number of participants can now double to 6,000
  • The measure aims to detect rare cases of heart inflammation seen in people under the age of 30 who have been vaccinated

Pfizer-BioNTech and Moderna are expanding the scope of their clinical trials of COVID-19 vaccines in children ages five to 11 at the urging of the US Food and Drug Administration (FDA).

Multiple sources told The New York Times that the aim is to detect cases of rare heart infections that have occurred in vaccinated people under the age of 30.

When the studies began, Pfizer and Moderna were asked to include 3,000 children between the ages of five and 11.

However, the companies are now being asked to double the number of pediatric participants.

Pfizer-BioNTech and Moderna are being asked by the FDA to expand the number of children ages 5-11 in their COVID-19 vaccine clinical trials.  Pictured: Eloise LaCour, three, to receive vaccine or placebo as part of Phase 1 clinical trials using Pfizer-BioNTech vaccine

Pfizer-BioNTech and Moderna are being asked by the FDA to expand the number of children ages 5-11 in their COVID-19 vaccine clinical trials. Pictured: Eloise LaCour, three, to receive vaccine or placebo as part of Phase 1 clinical trials using Pfizer-BioNTech vaccine

This is a latest news item and will be updated.

Advertisement

.